Abstract：Objective To investigate the safety and efficacy of stenting for symptomatic intracranial artery stenosis.Methods A retrospective analysis was conducted. Clinical data of 31 patients who underwent intracranial atherosclerotic stent implantation in the Department of Neurology of the First Affiliated Hospital of Army Medical University from September 2014 to August 2015 were included. The patients comprised 21 males and 10 females, aged 36-73 years old (mean, 57.00±9.87 years old). According to the stent type, the patients were divided into the self-expanding stent group (16 cases) and the balloon-mounted stent group (15 cases). Patients were followed up for more than 5 years, and endpoint events were observed and recorded. The endpoint events that occurred within 30 days after stenting events included stroke, transient ischemic attack, and death. The endpoint events that occurred 30 days to 5 years after stenting included ipsilateral ischemic stroke, cerebral hemorrhage, and vascular death.Results Thirty-one patients were followed up for 1-77 months (mean, 62.7±15.5 months). Four patients had endpoint events, including three deaths, within 5 years. Two cases of cerebral hemorrhage had endpoint events within 30 days after surgery, including 1 death. Two patients developed endpoint events in 30 days to 5 years; 2, 2, 4, 4, and 4 cumulative endpoint events occurred in 1 to 5 years, among them, 2 cases were increased in 3 years, 1 was ipsilateral ischemic stroke, and 1 was hemorrhagic stroke; all these patients died. No statistically significant difference was found between the self-expanding stent group and the balloon-mounted stent group for each endpoint event (all P values＞0.05).Conclusions Stenting for symptomatic intracranial arterial stenosis is safe and effective in both perioperative and long-term follow-up periods.
Redon J, Olsen MH, Cooper RS, et al. Stroke mortality and trends from 1990 to 2006 in 39 countries from Europe and Central Asia: implications for control of high blood pressure[J]. Eur Heart J, 2011, 32(11): 1424-1431. DOI:10.1093/eurheartj/ehr045.
[2]
Wong KS, Li H, Lam WW, et al. Progression of middle cerebral artery occlusive disease and its relationship with further vascular events after stroke[J]. Stroke, 2002, 33(2): 532-536. DOI:10.1161/hs0202.102602.
[3]
Gorelick PB, Wong KS, Bae HJ, et al. Large artery intracranial occlusive disease: a large worldwide burden but a relatively neglected frontier[J]. Stroke, 2008, 39(8): 2396-2399. DOI:10.1161/STROKEAHA.107.505776.
[4]
Wang Y, Zhao X, Liu L, et al. Prevalence and outcomes of symptomatic intracranial large artery stenoses and occlusions in China: the Chinese Intracranial Atherosclerosis (CICAS) study[J]. Stroke, 2014, 45(3): 663-669. DOI:10.1161/STROKEAHA.113.003508.
[5]
Chimowitz MI, Lynn MJ, Howlett-Smith H, et al. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis[J]. N Engl J Med, 2005, 352(13): 1305-1316. DOI:10.1056/NEJMoa043033.
[6]
Chimowitz MI, Lynn MJ, Derdeyn CP, et al. Stenting versus aggressive medical therapy for intracranial arterial stenosis[J]. N Engl J Med, 2011, 365(11): 993-1003. DOI:10.1056/NEJMoa1105335.
[7]
Zaidat OO, Fitzsimmons BF, Woodward BK, et al. Effect of a balloon-expandable intracranial stent vs medical therapy on risk of stroke in patients with symptomatic intracranial stenosis: the VISSIT randomized clinical trial[J]. JAMA, 2015, 313(12): 1240-1248. DOI:10.1001/jama.2015.1693.
[8]
Yu SC, Cheng HK, Cheng PW, et al. Angioplasty and stenting for intracranial atherosclerotic stenosis: position statement of the Hong Kong Society of Interventional and Therapeutic Neuroradiology[J]. Hong Kong Medical Journal, 2013, 19(1): 69-73.
[9]
Miao Z. Intracranial angioplasty and stenting before and after SAMMPRIS: “from simple to complex strategy - the Chinese experience”[J]. Front Neurol, 2014, 5: 129. DOI:10.3389/fneur.2014.00129.
[10]
Sangha RS, Naidech AM, Corado C, et al. Challenges in the medical management of symptomatic intracranial stenosis in an urban setting[J]. Stroke, 2017, 48(8): 2158-2163. DOI:10.1161/STROKEAHA.116.016254.
[11]
Miao Z, Zhang Y, Shuai J, et al. Thirty-day outcome of a multicenter registry study of stenting for symptomatic intracranial artery stenosis in China[J]. Stroke, 2015, 46(10): 2822-2829. DOI:10.1161/STROKEAHA.115.010549.
[12]
Ma N, Zhang Y, Shuai J, et al. Stenting for symptomatic intracranial arterial stenosis in China: 1-year outcome of a multicentre registry study[J]. Stroke Vasc Neurol, 2018, 3(3): 176-184. DOI:10.1136/svn-2017-000137.
[13]
Gao P, Wang D, Zhao Z, et al. Multicenter prospective trial of stent placement in patients with symptomatic high-grade intracranial stenosis[J]. AJNR Am J Neuroradiol, 2016, 37(7): 1275-1280. DOI:10.3174/ajnr.A4698.
[14]
Gao P, Jiao LQ, Ma Y, et al. Abstract 64: china angioplasty and stenting for symptomatic intracranial severe stenosis (CASSISS): a prospective, multicenter, randomized controlled trial after SAMMPRIS[C]. Stroke, 2018: 49. DOI:10.1161/str.49.suppl_1.64.
[15]
Samuels OB, Joseph GJ, Lynn MJ, et al. A standardized method for measuring intracranial arterial stenosis[J]. AJNR Am J Neuroradiol, 2000, 21(4): 643-646.
[16]
van Swieten JC, Koudstaal PJ, Visser MC, et al. Interobserver agreement for the assessment of handicap in stroke patients[J]. Stroke, 1988, 19(5): 604-607. DOI:10.1161/01.str.19.5.604.
[17]
Zhou Y, Wang L, Zhang JR, et al. Angioplasty and stenting for severe symptomatic atherosclerotic stenosis of intracranial vertebrobasilar artery[J]. J Clin Neurosci, 2019, 63: 17-21. DOI:10.1016/j.jocn.2019.02.017.
[18]
Gao F, Lo WJ, Sun X, et al. Selective use of transradial access for endovascular treatment of severe intracranial vertebrobasilar artery stenosis[J]. Clin Neurol Neurosurg, 2015, 134: 116-121. DOI:10.1016/j.clineuro.2015.04.015.
[19]
Xu H, Quan T, Zaidat OO, et al. Neuroform EZ stenting for symptomatic intracranial artery stenosis: 30 days outcomes in a high-volume stroke center[J]. Front Neurol, 2019, 10: 428. DOI:10.3389/fneur.2019.00428.
[20]
Liu L, Zhao X, Mo D, et al. Stenting for symptomatic intracranial vertebrobasilar artery stenosis: 30-day results in a high-volume stroke center[J]. Clin Neurol Neurosurg, 2016, 143: 132-138. DOI:10.1016/j.clineuro.2016.02.029.
[21]
Alexander MJ, Zauner A, Chaloupka JC, et al. WEAVE trial: final results in 152 on-label patients[J]. Stroke, 2019, 50(4): 889-894. DOI:10.1161/STROKEAHA.118.023996.
[22]
Vajda Z, Schmid E, Güthe T, et al. The modified Bose method for the endovascular treatment of intracranial atherosclerotic arterial stenoses using the Enterprise stent[J]. Neurosurgery, 2012, 70(1): 91-101; discussion 101. DOI:10.1227/NEU.0b013e31822dff0f.
[23]
Feng Z, Duan G, Zhang P, et al. Enterprise stent for the treatment of symptomatic intracranial atherosclerotic stenosis: an initial experience of 44 patients[J]. BMC Neurol, 2015, 15: 187. DOI:10.1186/s12883-015-0443-9.
[24]
Yu W, Jiang WJ. Stenting for intracranial stenosis: potential future for the prevention of disabling or fatal stroke[J]. Stroke Vasc Neurol, 2018, 3(3): 140-146. DOI:10.1136/svn-2018-000158.
2021, Vol. 26 
